Research programme: bone disorders and inflammatory disease therapeutics - Galapagos

Drug Profile

Research programme: bone disorders and inflammatory disease therapeutics - Galapagos

Alternative Names: Bone and joint disorder therapeutics - Galapagos; GLPG3121; GPLG 3121; GT146; GT328; GT442; Oral psoriasis therapy - Galapagos NV; Osteoporosis therapies - Galapagos; Rheumatoid arthritis therapies - Galapagos

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProSkelia
  • Developer Galapagos NV; Ghent University; Janssen Pharmaceutica; Pfizer
  • Class Antibodies; Small molecules
  • Mechanism of Action Integrin inhibitors; Osteogenesis stimulants; Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bone disorders; Inflammation; Osteoporosis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-disorders in Belgium
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Belgium
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoporosis in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top